The Trump administration’s sweeping tariff agenda – briefly tempered by a 90-day pause announced on 12 May – has reignited discussion around global supply chain resilience. While no significant effects are currently being felt in Australia’s aesthetics sector, many are watching closely.
The global aesthetics industry is navigating a shifting trade landscape, as the United States enacts new import tariffs on a broad range of goods, including medical devices. Aimed at bolstering domestic manufacturing, these policies could reshape cost structures across international markets, and Australia is not immune to these shifts.
For now, however, the impact on local shores remains muted — a ‘wait and see’ environment, buoyed by the increasingly sophisticated global infrastructures aesthetics manufacturers have built to withstand market shocks.
In April 2025, the US introduced a 10 percent global tariff on nearly all imported goods, with certain categories attracting significantly higher levies. Chinese active pharmaceutical ingredients (APIs), for instance, were hit with a 245 percent tariff, while medical devices from Canada and Mexico now face a 25 percent duty.
A temporary 90-day reprieve on some China-specific tariffs, announced on 12 May, has offered additional breathing room. Yet a baseline 10 percent duty on most imports — plus a 30 percent tariff on select Chinese parts — continues to reverberate through global logistics frameworks.
Despite these shifts, distributors and manufacturers are not yet reporting immediate effects on price or availability in the Australian market.
‘We haven’t seen or heard of any changes yet,’ says Matt Moncrieff, managing director of High Tech Medical, one of Australia’s leading distributors of aesthetic devices. ‘Manufacturers plan 6 to 12 months in advance — sometimes 18 months. Since COVID, they’ve become very good at hedging against supply shocks.’
Some manufacturers, such as BTL, are structurally less exposed to upstream disruption due to full in- house control of their production.
‘We’re in a fortunate position,’ says Gareth Pepper, Director ANZ BTL Aesthetics. ‘BTL designs and builds all its devices in-house, which means we’re not waiting on third-party suppliers. We have full control from start to finish, so our partners in Australia get what they need, when they need it, without disruption.’
‘THE TRUE IMPACT LIES IN THE INDIRECT TRANSMISSION OF COSTS, DRIVEN BY THE GLOBAL COMPLEXITY OF AESTHETIC PRODUCT SUPPLY CHAINS.’
Toxins & fillers: reprieves and ripple effects
Australia’s injectables market has long depended on international manufacturing. Botulinum toxin and dermal filler products are largely produced and vialed in the US, Europe and South Korea. Even when Australia is not directly subject to US tariffs, the true impact lies in the indirect transmission of costs, driven by the global complexity of aesthetic product supply chains.
Indirect costs could eventually emerge, particularly if input materials cross multiple borders.
Take dermal fillers, for instance: a vial assembled in Europe may contain lidocaine from the US, glass from China and piston seals from Japan. Each of these components could theoretically attract new tariffs along the way, gradually affecting the final landed cost in Australia.
Pharmaceuticals, including botulinum toxin, have initially been spared in Trump’s trade tariffs, but many components essential to injectable manufacturing have not. This includes pharmaceutical excipients, packaging materials and lab consumables – all now subject to new US trade penalties.
However, the exemption’s duration remains uncertain. On April 8, President Trump said that ‘major’ tariffs on pharmaceuticals is on the way as well. If that is put into effect, neuromodulators would no longer be exempt.
While neuromodulators have, for now, avoided tariffs, dermal fillers – classified as medical devices – are not as fortunate. These products, predominantly manufactured abroad, are subject to the new tariffs, potentially leading to increased costs for both providers and patients down the track, especially if current tariffs extend beyond the next 12 months.
Energy-based devices, an import-heavy market
Australia’s market for energy-based devices – including lasers, HIFU platforms, RF microneedling systems and EM contouring devices – is similarly import-heavy. The International Trade Administration estimates that 85 percent of Australia’s medical devices are imported.
These systems are rarely produced in a single country. A fractional laser console, for example, may incorporate German optics, Chinese semiconductors and Korean casings. If even one of those components becomes more expensive or harder to source, freight timelines can slip and margins tighten.
That said, local distributors report that their manufacturers have built in significant buffers. ‘Since Covid, they’ve forecasted well ahead – locking in prices, sourcing components early,’ notes Moncrieff. ‘That gives us more stability than people might expect.’
‘Our clients can expect consistency,’ says Pepper. ‘We’ve done the planning do that they don’t need to stockpile or worry about business impact.’
‘We build our own devices, ship direct and have local support. We hold stock locally and have a full team on the ground to support our clinics. We’re focused on keeping things simple, steady and reliable, no matter what the global landscape throws at us,’ he adds.
‘THE INTERNATIONAL TRADE ADMINISTRATION ESTIMATES THAT 85 PERCENT OF AUSTRALIA’S MEDICAL DEVICES ARE IMPORTED, WITH THE US ALONE SUPPLYING ABOUT 30 PERCENT.’
Medical-grade skincare: Slow ripple effects
Medical-grade skincare products — particularly those requiring TGA listing or ARTG registration — can also be subject to indirect trade impacts. Cosmeceuticals frequently include global actives like retinoids, peptides, PDRN and hyaluronic acid, some of which originate from Chinese or Korean labs now affected by tariffs.
So far, few distributors report meaningful disruptions. Many have long-standing relationships with contract manufacturers who adjust sourcing strategies proactively.
Even so, the sector remains exposed to cost creep, particularly where ingredients, packaging or formulation services come from tariff-affected regions. The scale of that impact, if any, may become clearer later in 2025.
High dependency, low control
Australia’s aesthetic marketplace is deeply globalised; our injectables and device landscape is populated almost entirely by globally manufactured technologies and overseas manufacturers.
The country’s limited domestic production base means it is especially exposed to any external shock – be it a pandemic or tariff escalation. And because Australia is not a primary market for most manufacturers, it typically follows US or EU pricing and supply trends rather than setting them.
The Australian skincare market also depends significantly on imports. According to a 2025 IBISWorld report, imports satisfy about 70 percent of domestic demand for skincare products, indicating a substantial reliance on foreign-made products in this category.
As a DFAT update in April 2025 acknowledged, ‘Australia’s trade exposure to US-China tensions is significant across healthcare categories. Market participants should expect parallel pressures even without reciprocal Australian tariffs.’
No red flags – yet
While the US tariffs have reignited debate around global supply chain risk, Australia’s aesthetic medicine market has not yet experienced direct fallout. Supply remains stable. Pricing, for now, is holding. And manufacturers appear to have learned important lessons from the pandemic, allowing them to navigate new geopolitical headwinds with greater foresight.
The true test may come later in 2025 or 2026 — once existing stock contracts expire and component costs begin to flow downstream. Until then, it’s business as usual for most Australian clinics. AMP
‘No Distruption yet’ for Australias aesthetic industry
‘At this stage, we’re not seeing any disruption to pricing or supply,’ says Matt Moncrieff, managing directorof High Tech Medical. ‘Global manufacturers are much more strategic post-Covid – many now forecast 12 to 18 months ahead, have built-in buffers to absorb volatility and overall have stronger infrastructures in place to manage global shifts.
‘It’s too early to draw conclusions, but the industry is far better prepared for uncertainty than it was five years ago. It’s definitely a case of ‘wait and see’, but if there any trickle-down changes to pricing or supply, it’s likely to show up months down the line, not in the immediate future.’
Gareth Pepper, Director ANZ BTL Aesthetics, says: ‘Since we manufacture in Europe and ship directly to Australia, we’ve avoided major price spikes and freight challenges. Our pricing has stayed consistent, and that’s something we’re extremely proud of.’
85% of medical devices in Australia are imported
Australia is a key export destination for US medical technology, ranking eighth globally and third within the Asia-Pacific region for US medical product exports.
In 2022 alone, Australia imported over US$1.5 billion in medical equipment and supplies from the United States, representing three percent of America’s total exports in this category.
Around 85 percent of Australia’s demand for medical devices and diagnostics is met through imports, while nearly all domestically produced medical technology is exported. The country’s top three import partners are the United States, China and Germany, with the US supplying 31 percent of total medical device imports.
Source: U.S. Department of Commerce – Trade.gov
